Global Information
회사소개 | 문의 | 비교리스트

FLT190 : 신약 인사이트와 시장 예측(2030년)

FLT190 - Emerging Drug Insight and Market Forecast - 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 09월 상품 코드 959698
페이지 정보 영문 50 Pages
US $ 3,250 ₩ 3,819,000 PDF (Single User License)
US $ 6,500 ₩ 7,638,000 PDF (Site License)
US $ 9,750 ₩ 11,458,000 PDF (Global License)

FLT190 : 신약 인사이트와 시장 예측(2030년) FLT190 - Emerging Drug Insight and Market Forecast - 2030
발행일 : 2020년 09월 페이지 정보 : 영문 50 Pages

FLT190은 차세대형 간 지향성 아데노연관바이러스(AAV) 기반 유전자 치료제로, 파브리병 치료제로서 Freeline Therapeutics에 의해 개발되었습니다. 효소 a 갈락토시다아제 α(GLA) 발현을 위해 유전자 치료 플랫폼을 사용한 전임상 데이터에서는 다양한 동물 모델에서 안전성과 유효성이 실증되고 있습니다. 이 의약품은 현재 임상시험 제I/II상 단계에 있습니다.

파브리병 치료제인 FLT190 시장 구조·동향에 대해 분석했으며, 제품 개요(용법·용량, 작용기서 등)과 관련 규제, 제품 개발·임상시험 진행 상황, 주요 7개국(미국, 유럽 5개국(독일, 프랑스, 이탈리아, 스페인, 영국), 일본) 시장 규모 동향 전망(2020-2030년), 시장 경쟁 상황·SWOT 분석, 기타 치료제와의 경쟁 상태, 자본 거래 동향, 향후 시장 성장 가능성 등을 조사·제시하고 있습니다.


제1장 의약품 개요

  • 제품 상세 정보
  • 작용기서
  • 용법·용량
  • 연구개발(R&D) 활동
    • 임상 개발
    • 안전성·유효성
  • 기타 개발 활동

제2장 시장 평가

  • 주요 7개국(7MM) 시장 분석
  • 미국 시장
  • 독일 시장
  • 프랑스 시장
  • 이탈리아 시장
  • 스페인 시장
  • 영국 시장
  • 일본 시장

제3장 SWOT 분석

제4장 애널리스트의 견해

제5장 시장 진출 기업

제6장 기타 새로운 치료법

제7장 부록

제8장 보고서 구입 옵션

KSM 20.09.16

List of Tables

  • Table 1 FLT190, Description
  • Table 2 FLT190, Clinical Trial Description
  • Table 3 FLT190, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of FLT190
  • Figure 2 Patent Details, FLT190
  • Figure 3 FLT190, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 FLT190, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 FLT190, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 FLT190, Japan Market Size from 2020 to 2030 (in Millions USD)

"FLT190 - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Fabry Disease in 7 Major Markets. A detailed picture of the FLT190 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

FLT 190 is a next generation liver directed adeno associated virus (AAV) based gene therapy, being developed by Freeline therapeutics, for the treatment of Fabry's disease. Preclinical data using our gene therapy platform for expression of the enzyme a galactosidase α (GLA) has demonstrated safety and efficacy in various animal models. The drug is currently in phase I/2 stage of development.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around FLT190.
  • The report contains forecasted sales for FLT190 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Fabry Disease.
  • The report also features the SWOT analysis with analyst insights and key findings of FLT190.


The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FLT190 Analytical Perspective by DelveInsight

  • In-depth FLT190 Market Assessment

This report provides a detailed market assessment of FLT190 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • FLT190 Clinical Assessment

The report provides the clinical trials information of FLT190 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Fabry Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence FLT190 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Fabry Disease are giving market competition to FLT190 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of FLT190.
  • Our in-depth analysis of the forecasted sales data of FLT190 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FLT190.

Key Questions:

  • Which company is developing FLT190 along with the phase of the clinical study?
  • What is the technology utilized in the development of FLT190?
  • What is the product type, route of administration and mechanism of action of FLT190?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FLT190 development?
  • What are the key designations that have been granted to FLT190?
  • What is the forecasted market scenario of FLT190?
  • What is the history of FLT190 and what is its future?
  • What is the forecasted sales of FLT190 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to FLT190?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

Back to Top
전화 문의